INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 410m ago
HOUSE PTR10m ago
SEC 13F10m ago
ROBINHOOD CHAIN10m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Cowan Elvia sold PCVX

SVP, Finance & CAO · Vaxcyte, Inc. · Common Stock

Side
SELL
Value
$146K
Shares
2,500
Price
$58.59
Executed
Mar 11, 2026
Disclosed
Mar 11, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Mar 11 executedMar 11, 2026 disclosed

PCVX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+8 / 25

    $146K reported value · 7.5% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PCVX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$116K
    1,907 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    2,250 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    6
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$21K
    343 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$12K
    2,250 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    3,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    3
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$36K
    586 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$147K
    2,414 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$78K
    3,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    19.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    19
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.56M
    18.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    7
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    18.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    2
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$96K
    18.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    10
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$492K
    19.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    20
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.65M
    19.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale
    		SELL$79K
    1,334 sh
    		Sep 9, 2026Sep 9, 2026
    traded Sep 9, 2026
    		+0dSEC FORM 4

    Evidence

    26
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale
    		SELL$84K
    1,381 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    15
    JL
    Jodar LuisChief Medical Officer
    PCVXVaxcyte, Inc.
    Grant or award
    		A—
    52.6K sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    15
    JL
    Jodar LuisChief Medical Officer
    PCVXVaxcyte, Inc.
    Grant or award
    		A—
    88.3K sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    9
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Tax withholding
    		F$80K
    1,327 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    15
    DS
    Dhaliwal Harpreet S.Chief Technical Ops Officer
    PCVXVaxcyte, Inc.
    Tax withholding
    		F$462K
    7,651 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001960048-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 11, 2026
    Published
    Mar 11, 2026
    Ingested by INSIDER
    Nov 5, 04:12 UTC
    Last re-read
    Nov 5, 04:12 UTC

    Extracted facts

    Filer
    Cowan Elvia
    Role
    SVP, Finance & CAO
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Vaxcyte, Inc.
    Ticker
    PCVX
    Shares
    2,500
    Price per share
    $58.59
    Value
    $146,482
    Execution date (reported)
    Mar 11, 2026
    Owned after transaction
    30.9K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 2,500
    • Price: $58.5927

    = $146,482

    What this establishes

    Cowan Elvia filed this Form 4 reporting a open-market sale of PCVX on Mar 11, 2026. It became public on Mar 11, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, Finance & CAO
    Cowan Elviacik:0001960048
    Issuer
    Vaxcyte, Inc.cik:0001649094

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.